Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 11Neoplasm Metastasis 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Hematologic Neoplasms 2Brain Neoplasms 2Uterine Neoplasms 1Urologic Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm, Residual 1Melanoma 1HER2-positive Breast Cancer 1HER2-Positive Primary Breast Cancer 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 3olaparib 2atezolizumab 2Trastuzumab 2zimberelimab 1tocilizumab 1spartalizumab 1pralsetinib 1pertuzumab 1ipatasertib 1inavolisib 1fludarabine 1entrectinib 1alectinib 1Radiotherapy 1Methotrexate 1Immune Checkpoint Inhibitors 1Docetaxel 1Cyclophosphamide 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Solid Tumors × Ado-Trastuzumab Emtansine × Clear all
NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

Phase 2 Active not recruiting
920 enrolled 1 FDA
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡